European vaccine makers want EU exemptions that would protect them if there are problems with new Covid-19 vaccines, and low interest rates have helped US homebuilder stocks surge to record highs. Plus, the FT’s James Fontanella-Khan explains why Ant Group chose to list its potentially record setting IPO outside the US.
Covid-19 vaccine makers lobby EU for legal protection
https://www.ft.com/content/12f7da5b-92c8-4050-bcea-e726b75eef4d?
Low rates help propel US homebuilder stocks to record highs
https://www.ft.com/content/9b54ab06-2d57-44a1-85c2-47c114589c22
Ant Group reveals $2.6bn profit as it files for blockbuster IPO
https://www.ft.com/content/b5f6fed2-2dcf-48dc-9097-a49bff5532dc
Hosted on Acast. See acast.com/privacy for more information.
Fler avsnitt av FT News Briefing
Visa alla avsnitt av FT News BriefingFT News Briefing med Financial Times finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
